Pre-made Atezolizumab benchmark antibody ( Whole mAb, anti-CD274/PD-L1 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Atezolizumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
| Products Name (INN Index) | Pre-Made Atezolizumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody |
|---|---|
| INN Name | Atezolizumab |
| Target | CD274 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 5x8l:FK:HM:GL:JO:SN |
| 99% SI Structure | 5xxy:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Amgen,ARCAGY/GINECO Group,BioLineRx,Chugai Pharmaceutical,Clovis Oncology,Dana-Farber Cancer Institute,Duke University,European Organisation for Research and Treatment of Cancer,Exelixis,Fondazione M |
| Conditions Approved | Non-small cell lung cancer,Urogenital cancer,Breast cancer,Small cell lung cancer |
| Conditions Active | Bladder cancer,Cervical cancer,Colorectal cancer,Fallopian tube cancer,Head and neck cancer,Liver cancer,Malignant melanoma,Ovarian cancer,Peritoneal cancer,Prostate cancer,Renal cell carcinoma,Anal |
| Conditions Discontinued | Hodgkin's disease,Myelodysplastic syndromes |
| Development Tech | Human Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | CD274/PD-L1 |
| Package |
